Raymond James Financial Inc. Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Raymond James Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,440 shares of the company’s stock, valued at approximately $68,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZNTL. Charles Schwab Investment Management Inc. raised its position in shares of Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Anfield Capital Management LLC increased its stake in Zentalis Pharmaceuticals by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock valued at $392,000 after purchasing an additional 64,659 shares during the last quarter. Barclays PLC raised its holdings in shares of Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares during the period. SG Americas Securities LLC lifted its position in shares of Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after buying an additional 30,240 shares during the last quarter. Finally, Savant Capital LLC bought a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth about $72,000.

Insiders Place Their Bets

In other news, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Stock Up 8.8 %

Shares of ZNTL stock opened at $1.23 on Monday. The stock has a 50-day simple moving average of $1.84 and a 200 day simple moving average of $2.64. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $13.77. The stock has a market capitalization of $88.33 million, a P/E ratio of -0.49 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ZNTL shares. Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. UBS Group cut their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.